

Article

# Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer

Marta Toledano-Fonseca, M. Teresa Cano, Elizabeth Inga, Rosa Rodríguez-Alonso, M. Auxiliadora Gómez-España, Silvia Guil-Luna, Rafael Mena-Osuna, Juan R. de la Haba-Rodríguez, Antonio Rodríguez-Ariza and Enrique Aranda

**Supplementary Materials:**

**Supplementary Table 1.** Results of baseline RAS mutation analysis in tissue and plasma.

| Patient ID | Tissue biopsy RAS status | Liquid biopsy RAS status     | Treatment                        |
|------------|--------------------------|------------------------------|----------------------------------|
| Patient 1  | KRAS Cdn 12              | WT                           | Gemcitabine+Nabpaclitaxel        |
| Patient 2  | WT                       | WT                           | Gemcitabine+Nabpaclitaxel        |
| Patient 3  | N/A1                     | KRAS Cdn 12                  | Gemcitabine+Nabpaclitaxel        |
| Patient 4  | KRAS Cdn 12              | KRAS Cdn 12                  | Gemcitabine+Nabpaclitaxel        |
| Patient 5  | KRAS Cdn 12              | KRAS Cdn 12                  | Gemcitabine+Nabpaclitaxel        |
| Patient 6  | KRAS Cdn 12              | KRAS Cdn 12                  | Gemcitabine+Nabpaclitaxel        |
| Patient 7  | N/A                      | KRAS Cdn 12                  | Gemcitabine+Nabpaclitaxel+FOLFOX |
| Patient 8  | N/A                      | KRAS Cdn 12                  | Gemcitabine                      |
| Patient 9  | WT                       | WT                           | Gemcitabine+Nabpaclitaxel        |
| Patient 10 | KRAS Cdn 12              | KRAS Cdn 12                  | Gemcitabine+Nabpaclitaxel        |
| Patient 11 | KRAS Cdn 12              | KRAS Cdn 12                  | Gemcitabine+Nabpaclitaxel        |
| Patient 12 | KRAS Cdn 12              | KRAS Cdn 12                  | Gemcitabine+Nabpaclitaxel+FOLFOX |
| Patient 13 | KRAS Cdn 61              | KRAS Cdn 61                  | Gemcitabine+Nabpaclitaxel        |
| Patient 14 | WT                       | KRAS Cdn 12                  | Gemcitabine+Nabpaclitaxel        |
| Patient 15 | KRAS Cdn 12              | WT                           | Gemcitabine+Nabpaclitaxel        |
| Patient 16 | KRAS Cdn 12              | KRAS Cdn 12                  | Gemcitabine+Nabpaclitaxel        |
| Patient 17 | N/A                      | KRAS Cdn 12                  | Gemcitabine+Nabpaclitaxel        |
| Patient 18 | WT                       | WT                           | Gemcitabine+Nabpaclitaxel        |
| Patient 19 | WT                       | KRAS Cdn 12                  | Gemcitabine+Nabpaclitaxel+FOLFOX |
| Patient 20 | WT                       | WT                           | Gemcitabine+Nabpaclitaxel        |
| Patient 21 | KRAS Cdn 12              | KRAS Cdn 12                  | Gemcitabine+Nabpaclitaxel        |
| Patient 22 | N/A                      | KRAS Cdn 12                  | No treatment                     |
| Patient 23 | KRAS Cdn 12              | KRAS Cdn 12                  | Gemcitabine+Nabpaclitaxel        |
| Patient 24 | N/A                      | KRAS Cdn 12                  | Gemcitabine+Nabpaclitaxel        |
| Patient 25 | KRAS Cdn 12              | KRAS Cdn 12                  | Gemcitabine+Nabpaclitaxel        |
| Patient 26 | N/A                      | KRAS Cdn 12 and NRAS Cdn 12  | No treatment                     |
| Patient 27 | KRAS Cdn 12              | KRAS Cdn 12 and NRAS Cdn 117 | Gemcitabine+Nabpaclitaxel        |
| Patient 28 | KRAS Cdn 12              | KRAS Cdn 12                  | Gemcitabine+Nabpaclitaxel        |
| Patient 29 | KRAS Cdn 12              | KRAS Cdn 12                  | Gemcitabine+Nabpaclitaxel+FOLFOX |
| Patient 30 | WT                       | KRAS Cdn 12                  | Gemcitabine+Nabpaclitaxel        |
| Patient 31 | N/A                      | WT                           | Gemcitabine+Nabpaclitaxel        |
| Patient 32 | WT                       | WT                           | Gemcitabine+Nabpaclitaxel        |
| Patient 33 | KRAS Cdn 12              | KRAS Cdn 12                  | Gemcitabine+Nabpaclitaxel        |

|            |             |             |                           |
|------------|-------------|-------------|---------------------------|
| Patient 34 | KRAS Cdn 12 | KRAS Cdn 12 | Gemcitabine+Nabpaclitaxel |
| Patient 35 | N/A         | KRAS Cdn 12 | Gemcitabine               |
| Patient 36 | KRAS Cdn 12 | WT          | FOLFIRINOX                |
| Patient 37 | N/A         | KRAS Cdn 12 | Gemcitabine               |
| Patient 38 | N/A         | NRAS Cdn 13 | FOLFIRINOX                |
| Patient 39 | KRAS Cdn 12 | WT          | Gemcitabine+Nabpaclitaxel |
| Patient 40 | KRAS Cdn 12 | KRAS Cdn 12 | FOLFIRINOX                |
| Patient 41 | KRAS Cdn 12 | KRAS Cdn 12 | Gemcitabine+Nabpaclitaxel |
| Patient 42 | WT          | KRAS Cdn 12 | No treatment              |
| Patient 43 | KRAS Cdn 12 | KRAS Cdn 12 | FOLFIRINOX                |
| Patient 44 | N/A         | KRAS Cdn 12 | Gemcitabine+Nabpaclitaxel |
| Patient 45 | KRAS Cdn 12 | KRAS Cdn 12 | Gemcitabine+Nabpaclitaxel |
| Patient 46 | N/A         | KRAS Cdn 12 | Gemcitabine+Nabpaclitaxel |
| Patient 47 | KRAS Cdn 12 | KRAS Cdn 12 | No treatment              |
| Patient 48 | KRAS Cdn 12 | KRAS Cdn 12 | FOLFIRINOX                |
| Patient 49 | KRAS Cdn 12 | KRAS Cdn 12 | FOLFIRINOX                |
| Patient 50 | KRAS Cdn 12 | KRAS Cdn 12 | Gemcitabine+Nabpaclitaxel |
| Patient 51 | N/A         | KRAS Cdn 12 | Gemcitabine+Nabpaclitaxel |
| Patient 52 | KRAS Cdn 12 | KRAS Cdn 12 | Gemcitabine+Nabpaclitaxel |
| Patient 53 | KRAS Cdn 13 | KRAS Cdn 13 | FOLFIRINOX                |
| Patient 54 | KRAS Cdn 12 | KRAS Cdn 12 | FOLFIRINOX                |
| Patient 55 | KRAS Cdn 12 | KRAS Cdn 12 | FOLFIRINOX                |
| Patient 56 | N/A         | WT          | FOLFIRINOX                |
| Patient 57 | KRAS Cdn 12 | WT          | FOLFIRINOX                |
| Patient 58 | N/A         | KRAS Cdn 12 | Gemcitabine+Nabpaclitaxel |
| Patient 59 | WT          | WT          | Gemcitabine+Nabpaclitaxel |
| Patient 60 | N/A         | WT          | Gemcitabine+Nabpaclitaxel |
| Patient 61 | N/A         | KRAS Cdn 12 | Gemcitabine+Nabpaclitaxel |



© 2020 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).